Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus AUREOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus AUREOMYCIN.
ACHROMYCIN vs AUREOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic